智飞生物(300122) - 投资者关系活动记录表

Financial Performance - In the first three quarters of 2021, the company achieved an operating income of 21.829 billion CNY, representing a year-on-year growth of 97.55% [1] - The net profit attributable to shareholders, after deducting non-recurring gains and losses, was 8.418 billion CNY, an increase of 239.06% compared to the same period last year [1] Product Development and Market Expansion - The company has actively promoted its products, including the COVID-19 vaccine, which has been approved for emergency use and is contributing to domestic epidemic prevention efforts while also being exported to international markets [2] - The company is focusing on the development of new vaccines and has obtained key data from Phase III clinical trials for its recombinant COVID-19 vaccine, demonstrating good safety and efficacy [2] Strategic Initiatives - The company is committed to a "technology + market" dual-driven development model, increasing R&D investment and advancing various projects [2] - The company is also preparing for the international certification of its products and aims to expand its global business footprint [2] HPV Vaccine Market Response - The company is monitoring the introduction of domestic HPV vaccines and is prepared to respond to market changes, ensuring a diverse range of vaccination options for the public [3] - As of mid-2021, the company has issued over 30 million doses of HPV vaccines, covering more than 10 million individuals [3] Tuberculosis Product Development - The company has launched two tuberculosis products, forming a comprehensive system for the diagnosis, prevention, and treatment of tuberculosis [4] - The newly approved product for preventing latent tuberculosis infections is the first of its kind in the market [4] R&D Pipeline Progress - The company has 26 projects in its R&D pipeline, with 16 projects entering the registration process [4] - Significant progress has been made in various vaccine projects, including the completion of clinical trials for several vaccines [4]